The use of a hypomethylating agent in combination with venetoclax in the R/R AML setting has been shown to produce response rates of between 12–51% in retrospective series, though significant heterogeneity is seen based on clinical (e.g., previous hypomethylating agent exposure) and genomic (e.g., higher response rate with IDH1/2 and NPM1 mutations) features [54,55,56,57,58]. The gene discussed is IDH1; the disease is acute myeloid leukemia.